BioLineRx Ltd.

TASE:BLRX Stock Report

Market Cap: ₪39.3m

BioLineRx Future Growth

Future criteria checks 2/6

BioLineRx's earnings are forecast to decline at 12.6% per annum while its annual revenue is expected to grow at 46% per year. EPS is expected to grow by 122.1% per annum.

Key information

-12.6%

Earnings growth rate

122.09%

EPS growth rate

Biotechs earnings growth31.9%
Revenue growth rate46.0%
Future return on equityn/a
Analyst coverage

Low

Last updated02 Jun 2026

Recent future growth updates

Recent updates

Analysis Article • Dec 23

BioLineRx Ltd.'s (TLV:BLRX) Revenues Are Not Doing Enough For Some Investors

BioLineRx Ltd.'s ( TLV:BLRX ) price-to-sales (or "P/S") ratio of 1x might make it look like a buy right now compared to...
Analysis Article • Jul 09

Why Investors Shouldn't Be Surprised By BioLineRx Ltd.'s (TLV:BLRX) 29% Share Price Plunge

The BioLineRx Ltd. ( TLV:BLRX ) share price has softened a substantial 29% over the previous 30 days, handing back much...
Analysis Article • Apr 02

Does BioLineRx (TLV:BLRX) Have A Healthy Balance Sheet?

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Analysis Article • Aug 25

BioLineRx (TLV:BLRX) Has Debt But No Earnings; Should You Worry?

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
Analysis Article • Apr 05

Health Check: How Prudently Does BioLineRx (TLV:BLRX) Use Debt?

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
Analysis Article • Jun 17

Is BioLineRx (TLV:BLRX) A Risky Investment?

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
Analysis Article • Feb 26

Is BioLineRx (TLV:BLRX) Using Debt In A Risky Way?

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
Analysis Article • Oct 17

Is BioLineRx (TLV:BLRX) Using Debt In A Risky Way?

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...

Earnings and Revenue Growth Forecasts

TASE:BLRX - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20286-19-26-262
12/31/20272-20-24-242
12/31/20262-144-132
3/31/20261-8-8-8N/A
12/31/20251-1-8-8N/A
9/30/202513-3-13-13N/A
6/30/202517-8-21-21N/A
3/31/202522-3-32-32N/A
12/31/202429-9-44-44N/A
9/30/202422-20-30-30N/A
6/30/202417-30-30-30N/A
3/31/202412-49-29-29N/A
12/31/20235-61-23-23N/A
9/30/2023N/A-52-34-33N/A
6/30/2023N/A-43-33-32N/A
3/31/2023N/A-32-29-29N/A
12/31/2022N/A-25-27-26N/A
9/30/2022N/A-24-26-26N/A
6/30/2022N/A-22-23-22N/A
3/31/2022N/A-22-23-23N/A
12/31/2021N/A-27-24-24N/A
9/30/2021N/A-35-24-24N/A
6/30/2021N/A-34-24-24N/A
3/31/2021N/A-34-23-23N/A
12/31/2020N/A-30-23-23N/A
9/30/2020N/A-28-23-23N/A
6/30/2020N/A-27-24-24N/A
3/31/2020N/A-26-25-25N/A
12/31/2019N/A-25N/A-23N/A
9/30/2019N/A-21N/A-22N/A
6/30/2019N/A-24N/A-22N/A
3/31/2019N/A-23N/A-22N/A
12/31/2018N/A-23N/A-24N/A
9/30/2018N/A-25N/A-25N/A
6/30/2018N/A-26N/A-26N/A
3/31/2018N/A-26N/A-24N/A
12/31/2017N/A-24N/A-21N/A
9/30/2017N/A-21N/A-18N/A
6/30/2017N/A-18N/A-15N/A
3/31/2017N/A-17N/A-14N/A
12/31/2016N/A-16N/A-15N/A
9/30/2016N/A-15N/A-14N/A
6/30/2016N/A-13N/A-14N/A
3/31/2016N/A-14N/A-15N/A
12/31/2015N/A-14N/A-14N/A
9/30/2015N/A-15N/A-16N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: BLRX is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: BLRX is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: BLRX is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: BLRX's revenue (46% per year) is forecast to grow faster than the IL market (10.2% per year).

High Growth Revenue: BLRX's revenue (46% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if BLRX's Return on Equity is forecast to be high in 3 years time

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/06/11 18:25
End of Day Share Price 2026/06/11 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

BioLineRx Ltd. is covered by 6 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Michael KingCitizens JMP Securities, LLC
Joseph PantginisH.C. Wainwright & Co.
Justin WalshJonesTrading Institutional Services, LLC